Literature DB >> 17610843

SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity.

Mélanie A Berta1, Nathalie Mazure, Maurice Hattab, Jacques Pouysségur, M Christiane Brahimi-Horn.   

Abstract

The hypoxic response of mammalian cells is controlled through a transcriptional pathway that is mediated by the hypoxia-inducible factor (HIF). Here, we show that HIF-1alpha undergoes post-translational modification by the three isoforms of the small ubiquitin-related modifier (SUMO-1, -2 and -3) in vitro in proximity to and within the oxygen-dependent degradation domain (ODDD). SUMO conjugation is promoted in vitro by the E3 SUMO ligase RanBP2/Nup538 and SUMO modification in vivo does not change HIF-1alpha turnover rate. Using cotransfection of siRNA targeted to endogenous HIF-1alpha together with HIF-1alpha siRNA-resistant expression vectors carrying mutations for SUMO modification we demonstrate increased hypoxia-response element-dependent transcriptional activity for SUMO-deficient HIF-1alpha. These results indicate that when HIF-1alpha is conjugated to SUMO its transcriptional activity is decreased and that this is not mediated by a change in the protein's half-life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610843     DOI: 10.1016/j.bbrc.2007.06.103

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  43 in total

1.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

Review 2.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

Review 3.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

Review 4.  Ubiquitin-proteasome system as a modulator of cell fate.

Authors:  Simon J Thompson; Liam T Loftus; Michelle D Ashley; Robert Meller
Journal:  Curr Opin Pharmacol       Date:  2007-11-05       Impact factor: 5.547

5.  NLRX1 Regulates Effector and Metabolic Functions of CD4+ T Cells.

Authors:  Andrew Leber; Raquel Hontecillas; Nuria Tubau-Juni; Victoria Zoccoli-Rodriguez; Matthew Hulver; Ryan McMillan; Kristin Eden; Irving C Allen; Josep Bassaganya-Riera
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

6.  RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.

Authors:  Martijn van Hagen; René M Overmeer; Sharareh S Abolvardi; Alfred C O Vertegaal
Journal:  Nucleic Acids Res       Date:  2009-12-21       Impact factor: 16.971

Review 7.  Emerging roles of SUMO modification in arthritis.

Authors:  Dongyao Yan; Francesca J Davis; Andrew D Sharrocks; Hee-Jeong Im
Journal:  Gene       Date:  2010-07-11       Impact factor: 3.688

8.  Xanthine oxidoreductase promotes the inflammatory state of mononuclear phagocytes through effects on chemokine expression, peroxisome proliferator-activated receptor-{gamma} sumoylation, and HIF-1{alpha}.

Authors:  Sophie Gibbings; Nancy D Elkins; Hillary Fitzgerald; Janice Tiao; Mari E Weyman; Gayle Shibao; Mehdi A Fini; Richard M Wright
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

9.  Adenosine signaling mediates SUMO-1 modification of IkappaBalpha during hypoxia and reoxygenation.

Authors:  Qian Liu; Jing Li; Joseph Khoury; Sean P Colgan; Juan C Ibla
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

10.  Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.

Authors:  Qiliang Cai; Suhbash C Verma; Pankaj Kumar; Michelle Ma; Erle S Robertson
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.